Abstract
This study used Taiwan’s National Health Insurance claim database (years 2000–2005) to examine how thiazolidinediones (TZD), a new class of drugs for diabetes, penetrated into Taiwan’s hospitals, and its association with the concentration of all diabetes drugs at the hospital level. We collected 72 monthly summaries of diabetes prescriptions from all hospitals in Taiwan. Hospital-level pharmaceutical concentration was measured by penetration of TZD, defined as monthly market share of TZD in each hospital. Concentration of diabetes drugs was measured by Herfindahl–Hirschman indices. We found a negative association (coefficient = −0.3610) between TZD penetration and concentration of diabetes drug but a positive association between penetration of TZD and the volume of prescribed diabetes drugs (coefficient = 0.4088). In conclusion, hospital characteristics and volume of services determined the concentration of pharmaceuticals at the institution level, reflecting the heterogeneous competition between pharmaceutical companies within each hospital. Institution-level pharmaceutical concentration influences the adoption and penetration of new drugs.
Similar content being viewed by others
References
Cutler, D.M., McClellan, M., Newhouse, J.P., Remler, D.: Are medical prices declining? Evidence from heart attack treatments. Q. J. Econ. 113, 991 (1998)
Dozet, A., Lyttkens, C.H., Nystedt, P.: Health care for the elderly: two cases of technology diffusion. Soc. Sci. Med. 54, 49 (2002)
Baker, L.C.: Managed care and technology adoption in health care: evidence from magnetic resonance imaging. J. Health Econ. 20, 395 (2001)
Baker, L.C., Phibbs, C.S.: Managed care, technology adoption and health care: the adoption of neonatal intensive care. Rand J. Econ. 33, 524 (2002)
Burke, M.A., Fournier, G.M., Prasad, K.: The diffusion of a medical innovation: is success in the stars? South. Econ. J. 73, 588 (2007)
Poulsen, P.B., Vondeling, H., Dirksen, C.D., Adamsen, S., Go, P.M.N.Y.H., Ament, A.J.H.: Timing of adoption of laparoscopic cholecystectomy in Denmark and in The Netherlands: a comparative study. Health Policy 55, 85 (2001)
Moloney, T.W., Rogers, D.E.: Medical technology—a different view of the contentious debate over costs. N. Engl. J. Med. 301, 1413 (1979)
Rudholm, N.: Competition and substitutability in the Swedish pharmaceuticals market. Appl. Econ. 35, 1609 (2003)
Bae, J.P.: Drug patent expirations and speed of generic entry. Health Serv. Res. 32, 87 (1997)
Berndt, E.R., Bui, L., Reiley, D.R., Urban, G.L.: Information, marketing, and pricing in the US antiulcer drug market. Am. Econ. Rev. 85, 100 (1995)
Ellison, S.F., Cockburn, I., Griliches, Z., Hausman, J.: Characteristics of demand for pharmaceutical products: an examination of four cephalosporins. Rand J. Econ. 28, 426 (1997)
Grabowski, H.G., Vernon, J.M.: Brand loyalty, entry and price competition in pharmaceuticals after the 1984 Drug Act. J. Law Econ. 35, 331 (1992)
Rudholm, N.: Entry and the number of firms in the Swedish pharmaceuticals market. Rev. Ind. Org. 19, 351 (2001)
Acemoglu, D., Linn, J.: Market size in innovation: theory and evidence from the pharmaceutical industry. Q. J. Econ. 119, 1049 (2004)
Morton, F.M.S.: Entry decisions in the generic pharmaceutical industry. Rand J. Econ. 30, 421 (1999)
Aronsson, T., Bergman, M.A., Rudholm, N.: The impact of generic drug competition on brand name market shares—evidence from micro data. Rev. Ind. Org. 19, 423 (2001)
Frank, R.G., Salkever, D.S.: Generic entry and the pricing of pharmaceuticals. J. Econ. Manag. Strategy 6, 75 (1997)
Hudson, J.: Pricing dynamics in the pharmaceutical industry. Appl. Econ. 24, 103 (1992)
Caves, R.E., Whinston, M.D., Hurwitz, M.A.: Patent expiration, entry, and competition in the US pharmaceutical industry. Brookings Pap. Econ. Act. 1991, 1 (1991)
Frank, R., Salkever, D.S.: Pricing, patent loss and the market for pharmaceuticals. South. Econ. J. 59, 165 (1992)
Frank, R.G.: Prescription drug prices: why do some pay more than others do? Health Aff. 20, 115 (2001)
Saha, A., Grabowski, H., Birnbaum, H., Greenberg, P., Bizan, O.: Generic competition in the US pharmaceutical industry. Int. J. Econ. Bus. 13, 15 (2006)
Rogers, E.M.: Diffusion of innovations. Simon and Schuster, New York (2003)
Hellerstein, J.K.: The importance of the physician in the generic versus trade-name prescription decision. Rand J. Econ. 29, 108 (1998)
Pauly, M.V.: Monopsony power in health insurance: thinking straight while standing on your head. J. Health Econ. 6, 73 (1987)
Snyder, C.M.: Why do larger buyers pay lower prices? Intense supplier competition. Econ. Lett. 58, 205 (1998)
Dusing, M.L., Guo, J.J., Kelton, C.M., Pasquale, M.K.: Competition and price discounts for a hospital buyer in the anti-infective pharmaceutical market. J. Pharm. Finan. Econ. Pol. 14, 59 (2005)
Martin, S.: Market power and/or efficiency? Rev. Econ. Stat. 70, 331 (1988)
Staten, M., Umbeck, J., Dunkelberg, W.: Market share/market power revisited : a new test for an old theory. J. Health Econ. 7, 73 (1988)
Hsieh, C.-R., Sloan, F.A.: Adoption of pharmaceutical innovation and the growth of drug expenditure in Taiwan: is it cost effective? Value Health. 11, 334 (2008)
BNHI: National Health Insurance Statistics Report. Bureau of National Health Insurance, Taipei (2008)
BNHI. National Health Insurance Act. Available at: http://www.nhi.gov.tw/english. Accessed 5 May 2009
BNHI. Drug Formulary of National Health Insurance. 2009. Available at: http://www.nhi.gov.tw/webdata/webdata.asp?menu=3&menu_id=56&webdata_id=1099&WD_ID=. Accessed 6 May 2009
Lee, Y.-C., Yang, M.-C., Huang, Y.-T., Liu, C.-H., Chen, S.-B.: Impacts of cost containment strategies on pharmaceutical expenditures of the National Health Insurance in Taiwan, 1996–2003. Pharmacoeconomics 24, 891 (2006)
Diamant, M., Heine, R.J.: Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence. Drugs. 63, 1373 (2003)
Cohen, F.J., Neslusan, C.A., Conklin, J.E., Song, X.: Recent antihyperglycemic prescribing trends for US privately insured patients with type 2 diabetes. Diabetes Care 26, 1847 (2003)
Laird, N.M., Ware, J.H.: Random-effects models for longitudinal data. Biometrics 38, 963 (1982)
Liang, K.-Y., Zeger, S.L.: Longitudinal data analysis using generalized linear models. Biometrika 73, 13 (1986)
Zeger, S.L., Liang, K.-Y.: Longitudinal data analysis for discrete and continuous outcomes. Biometrics 42, 121 (1986)
Acknowledgment
This research was supported by one grant from the intramural grant of National Health Research Institutes (grant number: HP-097-PP-04). We would also like to thank Mr. James Steed for his assistance in editing this manuscript.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tsai, YW., Wen, YW., Huang, WF. et al. Pharmaceutical penetration of new drug and pharmaceutical market structure in Taiwan: hospital-level prescription of thiazolidinediones for diabetes. Eur J Health Econ 11, 279–290 (2010). https://doi.org/10.1007/s10198-009-0174-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10198-009-0174-1